Not changes in heart failure therapy but patient characteristics at admission predict unsuccessful guidance of therapy to a target of more than 30% NT-proBNP reduction
The diagnostic and economic implications of using a plasma nt-probnp of 300 or 400ng/litre as the threshold for ruling out the diagnosis of heart failure in a non selected british population